Table 1.

The sameness and difference between Ranibizumab and Bevacizumab.

	Ranibizumab	Bevacizumab
The sameness
Target	VEGF	VEGF
Product	Monoclonal antibody	Monoclonal antibody
Epitope	Receptor-binding region	Receptor-binding region
The difference
Molecular weight	48.39 kDa	149 kDa
Half-life	3 days	17-21 days
Glycosylate	No	Yes
Expression system	E. coli	CHO cells
Effectiveness	Strong	Strong
Safety	Uncertain	Uncertain
Cost	$1950 per dose	$50 per dose
FDA-approved	For AMD	For cancer